Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Verona Pharma plc (NASDAQ:VRNA) Q1 2019 Results Earnings Conference Call May 07 2019, 08:00 AM ET Company Participants Stephanie Carrington - Investor Relations

Read more

Verona Pharma reports Q1 results
06:44am, Tuesday, 07'th May 2019

Read more

Wall Street brokerages expect VERONA PHARMA P/S (NASDAQ:VRNA) to report earnings of ($0.58) per share for the current quarter, according to Zacks. Zero analysts have made estimates for VERONA PHARMA P

Read more

Zacks Investment Research upgraded shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. The brokerage currently ha

Read more

VERONA PHARMA P/S (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks,

Read more

Verona Pharma Plc ADR (VRNA) are in focus as we look at near-term expected movement. The reading from the 40-day commodity channel index is currently Buy. The CCI indicator is mainly used to identify

Read more

Verona Pharma plc (NASDAQ:VRNA) and Orchard Therapeutics plc (NASDAQ:ORTX), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, instit

Read more

VERONA PHARMA P/S (NASDAQ:VRNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $7.00 price obj

Read more

Wall Street brokerages predict that VERONA PHARMA P/S (NASDAQ:VRNA) will report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates

Read more

VERONA PHARMA P/S (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday. According to

Read more

Zacks Investment Research upgraded shares of VERONA PHARMA P/S (NASDAQ:VRNA) from a hold rating to a buy rating in a report published on Thursday morning. They currently have $7.00 target price on the

Read more

Investors might be looking to focus on some longer-term indicators on shares of Verona Pharma Plc ADR (VRNA). The 100-day moving average verse price signal is Sell. This is the signal from the 100-day

Read more

Both Verona Pharma plc (NASDAQ:VRNA) and Enochian Biosciences Inc. (NASDAQ:ENOB) are each other’s competitor in the Biotechnology industry. Thus the contrast of their institutional ownership, profit

Read more

Immuron Limited (NASDAQ:IMRN) and Verona Pharma plc (NASDAQ:VRNA), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analys

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank